Alicyclic Diaza Compounds for Hypoxic Phototherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phototherapeutic agents primarily rely on the Type 2 mechanism, which requires oxygen and has limitations, particularly in hypoxic environments, while Type 1 agents, which do not require oxygen, have been underdeveloped despite their potential for enhanced efficacy under such conditions.
Innovation Solution
Development of optical agents comprising alicyclic diaza compounds with a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species for targeted tissue damage, including compounds with specific aromatic and heterocyclic groups and targeting ligands for enhanced specificity and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Type 2 phototherapeutic agents are used, then therapeutic effect is achieved in normoxic conditions, but efficacy is limited in hypoxic environments
Solution Approach 1:
The patent changes the mechanistic parameter of phototherapy from oxygen-dependent (Type 2) to oxygen-independent (Type 1) by using photosensitizers that generate reactive species through electron transfer rather than energy transfer to oxygen. This allows the therapeutic agent to function reliably across varying oxygen conditions, particularly in hypoxic tumor microenvironments where Type 2 agents fail.
2Adaptability or versatility
If Type 1 phototherapeutic agents are developed, then efficacy in hypoxic conditions is improved, but these agents have been underdeveloped despite their potential
Solution Approach 1:
The patent segments the phototherapy approach into distinct mechanistic pathways (Type 1 electron transfer vs. Type 2 energy transfer) and focuses on developing Type 1 agents with specific molecular structures. By categorizing and systematically developing Type 1 photosensitizers with appropriate HOMO-LUMO gaps and redox potentials, the patent makes the underdeveloped Type 1 approach more tractable and manufacturable.
3Length of stationary object
If optical agents absorb in the visible and NIR region, then penetration depth in biological media is increased, but selectivity for target tissue must be maintained
Solution Approach 1:
The patent employs composite molecular structures combining photosensitizer cores with targeting moieties (such as peptides, antibodies, or small molecules) that provide tissue specificity. This composite approach allows the optical agent to maintain deep tissue penetration through NIR absorption while achieving selective accumulation in target tissues through the attached targeting components, resolving the contradiction between penetration depth and selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents provide effective and selective tissue damage in hypoxic conditions, complementing existing Type 2 agents and expanding therapeutic options by utilizing a two-step process that does not rely on oxygen production, potentially offering improved therapeutic outcomes.
Implementation Method 1
compounds with a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species for targeted tissue damage
Data Source
AI summary
The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising alicyclic diaza compounds, including 1,2 diaza heterocyclic compounds, having a photolabile N—N bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic aromatic group. In some embodiments, for example, the invention provides alicyclic diaza compounds for phototherapeutic methods having a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species, such as radicals, ions, etc., that achieve a desired therapeutic effect, such as selective and/or localized tissue damage and/or cell death.